All patients
age >= 60 yr autoimmune disease invasive ventilation no oxygen needed non invasive oxygen
corticosteroids in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
Rashad, 2021 2.86 [1.36; 6.01]
Rashad, 2021 0.35 [0.17; 0.74]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Tang X, 2020 0.98 [0.93; 1.02]
0.97 [0.74 ; 1.27 ] GLUCOCOVID, 2020, Jamaati, 2021, Metcovid, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 8 58% 1,367 moderate not evaluable death or transfer to ICUdetailed results GLUCOCOVID, 2020 0.68 [0.37; 1.25]
0.68 [0.37 ; 1.25 ] GLUCOCOVID, 2020 1 0% 63 NA not evaluable deathsdetailed results Albani, 2020 1.15 [0.91; 1.46]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
Fernández Cruz, 2020 0.34 [0.12; 0.98]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Guan, 2020 0.67 [0.22; 2.09]
Jamaati, 2021 1.19 [0.38; 3.72]
Jianfeng, 2020 2.83 [1.72; 4.65]
Lu, 2020 3.28 [0.99; 10.90]
Majmundar, 2020 0.53 [0.22; 1.29]
Metcovid, 2020 0.92 [0.67; 1.28]
Monreal, 2020 (REV) 0.41 [0.26; 0.63]
Raef, 2020 0.45 [0.22; 0.92]
Ranjbar, 2021 0.40 [0.15; 1.08]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rodriguez-Bano (CS pulse dose), 2020 0.64 [0.31; 1.33]
Rodriguez-Bano (intermediate-high dose CS), 2020 1.21 [0.62; 2.36]
Salton (Methylprednisolone), 2020 0.29 [0.12; 0.72]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tang X, 2020 0.98 [0.93; 1.02]
Wang, 2020 1.58 [0.13; 18.81]
Wu, 2020 0.38 [0.20; 0.72]
Zhou, 2020 3.18 [1.63; 6.19]
0.84 [0.72 ; 0.98 ] Albani, 2020, CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Edalatifard, 2020, Fernández Cruz, 2020, GLUCOCOVID, 2020, Guan, 2020, Jamaati, 2021, Jianfeng, 2020, Lu, 2020, Majmundar, 2020, Metcovid, 2020, Monreal, 2020 (REV), Raef, 2020, Ranjbar, 2021, Rashad, 2021, Rashad, 2021, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rodriguez-Bano (CS pulse dose), 2020, Rodriguez-Bano (intermediate-high dose CS), 2020, Salton (Methylprednisolone), 2020, Steroids-SARI, 2020, Tang X, 2020, Wang, 2020, Wu, 2020, Zhou, 2020 29 76% 12,522 moderate low deaths (time to event analysis only)detailed results Edalatifard, 2020 0.29 [0.15; 0.56]
Jianfeng, 2020 3.02 [1.59; 5.73]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Salton (Methylprednisolone), 2020 0.29 [0.12; 0.72]
0.83 [0.46 ; 1.52 ] Edalatifard, 2020, Jianfeng, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Salton (Methylprednisolone), 2020 7 86% 1,031 serious not evaluable clinical deteriorationdetailed results CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
Salton (Methylprednisolone), 2020 0.41 [0.24; 0.71]
Tang X, 2020 1.00 [0.13; 7.45]
Yan et al., 2020 7.56 [1.17; 48.89]
0.78 [0.36 ; 1.70 ] CODEX (Tomazini), 2020, Salton (Methylprednisolone), 2020, Tang X, 2020, Yan et al., 2020 4 68% 558 serious not evaluable clinical improvementdetailed results Edalatifard, 2020 12.00 [2.39; 60.20]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
Tang X, 2020 1.04 [0.67; 1.62]
1.44 [0.89 ; 2.33 ] Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 4 65% 686 serious not evaluable clinical improvement (14-day)detailed results REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Tang X, 2020 1.33 [0.57; 3.11]
1.18 [0.87 ; 1.59 ] REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 3 0% 584 serious not evaluable clinical improvement (time to event analysis only)detailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
Rodriguez-Bano (CS pulse dose), 2020 0.61 [0.43; 0.86]
Rodriguez-Bano (intermediate-high dose CS), 2020 1.00 [0.71; 1.40]
0.92 [0.71 ; 1.20 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rodriguez-Bano (CS pulse dose), 2020, Rodriguez-Bano (intermediate-high dose CS), 2020 6 61% 6,244 low not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
Majmundar, 2020 3.65 [2.20; 6.06]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
1.84 [0.83 ; 4.07 ] CAPE-COVID, 2020, Majmundar, 2020, RECOVERY dexamethasone, 2020 3 91% 6,779 low not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
Jamaati, 2021 1.38 [0.45; 4.20]
Li (Methylprednisolone, Shanghai cohort), 2020 0.24 [0.07; 0.87]
Majmundar, 2020 0.31 [0.14; 0.69]
Metcovid, 2020 1.19 [0.56; 2.49]
Ranjbar, 2021 0.36 [0.13; 0.97]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Salton (Methylprednisolone), 2020 0.50 [0.24; 1.04]
0.64 [0.45 ; 0.92 ] CAPE-COVID, 2020, Jamaati, 2021, Li (Methylprednisolone, Shanghai cohort), 2020, Majmundar, 2020, Metcovid, 2020, Ranjbar, 2021, RECOVERY dexamethasone, 2020, Salton (Methylprednisolone), 2020 8 49% 6,337 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
4.89 [1.15 ; 20.79 ] Jamaati, 2021 1 0% 50 NA not evaluable viral clearance detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable viral clearance (time to event analysis only)detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable ICU admissiondetailed results Albani, 2020 0.48 [0.34; 0.67]
GLUCOCOVID, 2020 0.85 [0.27; 2.67]
Majmundar, 2020 0.16 [0.07; 0.35]
Salton (Methylprednisolone), 2020 0.51 [0.25; 1.06]
Tang X, 2020 1.00 [0.13; 7.45]
0.44 [0.26 ; 0.74 ] Albani, 2020, GLUCOCOVID, 2020, Majmundar, 2020, Salton (Methylprednisolone), 2020, Tang X, 2020 5 54% 1,931 low not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
Edalatifard, 2020 0.81 [0.11; 6.17]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
1.06 [0.41 ; 2.77 ] CODEX (Tomazini), 2020, Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 4 17% 841 serious not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
0.91 [0.66 ; 1.25 ] CAPE-COVID, 2020, Metcovid, 2020 2 0% 542 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-24 22:42 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 522,582,666,1149,1150,737,544,733
- roots T: 290
